Related Experiment Video
Updated: May 7, 2026
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Emetine dihydrochloride: a novel therapy for bladder cancer
Kimberly E Foreman1, John N Jesse2, Paul C Kuo3
1Department of Pathology, Loyola University Chicago, Maywood, Illinois; Stritch School of Medicine, Loyola University Chicago, Maywood, Illinois; Oncology Institute, Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, Illinois.
Purpose:
Current cisplatin based therapies for stage IV bladder cancer show 4% to 20% 5-year survival, underscoring the need to develop novel therapies for these patients. In the 1970s the natural alkaloid emetine dihydrochloride demonstrated modest anticancer efficacy as a single agent in clinical trials but this was not pursued. Groups recently reported that emetine induced apoptosis in leukemia cell lines, which was enhanced by cisplatin. We determined the antiproliferative effects of emetine with and without cisplatin in bladder cancer cells.
Materials And Methods:
Human bladder cancer cell lines and normal human urothelial cell cultures were treated with emetine and/or cisplatin. We measured cell proliferation and evaluated synergy using the Chou-Talalay method. The combination index was calculated. Cell cycle analysis was done and caspase activation was evaluated to assess growth arrest and apoptosis.
Results:
Emetine and cisplatin individually inhibited bladder cancer cell proliferation. When combined, emetine and cisplatin acted synergistically to inhibit tumor cell proliferation with combination index values reflecting moderate to strong synergy. Normal urothelial cells were relatively resistant to this treatment. Emetine alone and combined with cisplatin appeared to primarily induce tumor cell growth arrest and not apoptosis.
Conclusions:
To our knowledge this study demonstrates for the first time that emetine has in vitro antiproliferative activity against bladder cancer cell lines at nanomolar concentrations but little effect on normal urothelial cells. Moreover, emetine and cisplatin worked synergistically to inhibit tumor cell proliferation. Results suggest that combined emetine and cisplatin based chemotherapy may benefit patients with bladder cancer.
Insights
Emetine and cisplatin show synergistic effects against bladder cancer cells in vitro, offering a potential new chemotherapy option. This combination effectively inhibits tumor growth with minimal impact on normal cells.
Area of Science:
- Oncology
- Pharmacology
- Cell Biology
Background:
- Current cisplatin-based therapies for stage IV bladder cancer have limited efficacy, with 5-year survival rates between 4% and 20%.
- The natural alkaloid emetine dihydrochloride showed modest anticancer activity in the 1970s but was not further developed.
- Recent studies indicate emetine induces apoptosis in leukemia cell lines, an effect potentiated by cisplatin.
Purpose of the Study:
- To investigate the antiproliferative effects of emetine, alone and in combination with cisplatin, on human bladder cancer cells.
- To evaluate the synergistic interaction between emetine and cisplatin in inhibiting bladder cancer cell proliferation.
- To assess the differential effects of the combination therapy on cancer cells versus normal urothelial cells.
Main Methods:
- Human bladder cancer cell lines and normal urothelial cells were treated with emetine and/or cisplatin.
- Cell proliferation was measured, and synergy was assessed using the Chou-Talalay method (Combination Index).
- Cell cycle progression and caspase activation were analyzed to determine mechanisms of growth inhibition and apoptosis.
Main Results:
- Both emetine and cisplatin inhibited bladder cancer cell proliferation individually.
- Emetine and cisplatin demonstrated synergistic antiproliferative effects on tumor cells, with combination index values indicating moderate to strong synergy.
- Normal urothelial cells exhibited relative resistance to the combined treatment.
- Emetine, alone and combined with cisplatin, primarily induced tumor cell growth arrest rather than apoptosis.
Conclusions:
- Emetine exhibits in vitro antiproliferative activity against bladder cancer cell lines at nanomolar concentrations.
- Emetine and cisplatin act synergistically to inhibit bladder cancer cell proliferation, with minimal effects on normal urothelial cells.
- Combined emetine and cisplatin chemotherapy presents a promising therapeutic strategy for bladder cancer patients.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists